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re-Operative
ardiac Risk Assessment
n Noncardiac Surgery
re Natriuretic
eptides the Magic Bullet?*
aniel Bolliger, MD, Manfred D. Seeberger, MD,
iodrag Filipovic, MD
asel, Switzerland
atriuretic peptides (NPs) are well-established risk markers
n a broad range of acute (1,2) and chronic (3–5) cardiac
iseases. In addition, they are the basis of important
iagnostic and therapeutic decisions (6–8). In nonsurgical
atients, NPs fulfill all the recently published criteria for
linically useful risk markers (9): prospective validation of an
ncremental prognostic value, evidence for changes in clin-
cal management, improvement in outcome on the basis of
he changes made, and cost-effectiveness of the analysis.
onversely, in surgical patients, the role of NPs as clinical
isk markers is far less well established. Independent assess-
ent of their value in surgical patients is mandatory because
he perioperative period is complicated by specific problems,
or example, rapid hemodynamic changes, exaggerated
tress response and hypercoagulability causing myocardial
schemia, heart failure, arrhythmias and renal failure.
See page 1599
In this issue of the Journal, Karthikeyan et al. (10) present
heir meta-analysis of the predictive value of NPs (brain
atriuretic peptide [BNP] and N-terminal pro-brain natri-
retic peptide [NT-proBNP]) on adverse cardiovascular
utcomes in patients undergoing noncardiac surgery. The
uthors analyzed 9 studies including 3,200 patients to
etermine the association of pre-operatively elevated NP
evels with major adverse cardiac events (MACE) within 30
ays after noncardiac surgery. One-quarter of the patients
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Anesthesia, University of Basel Hospital, Basel,
witzerland. Roche Diagnostics Switzerland provided kits for assessment of NT-
roBNP in patients included in study NCT00286585, for which Dr. Seeberger isC
enior investigator; this is an investigator-initiated study. Dr. Filipovic is a co-
nvestigator of this study.ad elevated levels of the NPs, and 9.6% of the included
atients experienced at least 1 perioperative MACE. After
djustment for other known risk factors, the pooled data
howed an adjusted odds ratio of 19.3 (95% confidence
nterval: 8.5 to 43.7) for MACE in case of elevated NP
evels. These results agree with another recent meta-analysis
hat reported an unadjusted odds ratio of 17.37 (95%
onfidence interval: 3.31 to 91.15) for MACE within 30
ays among patients undergoing vascular surgery (11).
espite many well-acknowledged shortcomings and heter-
geneities of the studies included in the meta-analysis,
arthikeyan et al. (10) found clear evidence for the associ-
tion between pre-operatively elevated levels of NPs and
ost-operative occurrence of MACE.
From a clinical point of view, it is equally important to be
ware of the negative predictive value of the NPs, in other
ords, the association between nonelevated levels of the
Ps and favorable post-operative outcome. For patients
ndergoing major vascular surgery, we have found that the
egative predictive value of BNP levels50 pg/ml is as high
s 0.965 (95% confidence interval: 0.879 to 0.996) (12).
his finding is in agreement with a previous study of
atients undergoing nonvascular surgery (13) and with the
eta-analysis by Rodseth et al. (11) of patients undergoing
ascular surgery suggesting that patients with normal levels
f NPs may proceed directly to surgery with no additional
re-operative cardiac testing. One may speculate that this
pproach is very likely to be cost effective, but this hypoth-
sis needs to be proved in a future prospective study.
Evidence for changes in clinical management and im-
rovement in outcome on the basis of the test results are
urther criteria for the usefulness of risk makers. Improved
utcome for BNP-guided management of patients with
eart failure has been demonstrated in nonsurgical settings
6,8), but data for surgical patients are missing. Based on the
vailable data, the importance and meaning of pre-
peratively elevated levels of NPs remain unclear: Should
he patients undergo further cardiac testing? Should cardiac
edication be adjusted? Should perioperative monitoring be
ore invasive or should the post-operative stay in an
ntensive care unit be prolonged?
Another unsolved issue is the optimal time for pre-
perative NP testing. Initiation of a new therapy on the day
efore surgery does not seem to be a promising approach.
here is strong evidence for both statins (14,15) and
eta-blockers (16,17) that perioperative treatment is bene-
cial only if initiated at least several days to weeks before
urgery. Based on the time requirements and the positive
nd negative predictive values of NP testing, the following
pproach seems reasonable: Analysis of BNP or NT-
roBNP should be performed 4 to 5 weeks before scheduled
urgery in cases of intermediate- to high-risk surgery and
resence of clinical risk factors and/or reduced physical
apacity according to the current American College of
ardiology/American Heart Association guidelines (18). If
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Natriuretic Peptides in Noncardiac Surgery October 20, 2009:1607–8P levels are below a discrimination threshold (that still has
o be determined) and the patient is clinically stable, the
atient can proceed with surgery without the need for
urther testing. If NP levels are above the threshold, further
esting, optimization of medical therapy, and—rarely—
nvasive therapy should be performed. For these patients,
epeat testing shortly before surgery might allow for adjust-
ent of perioperative treatment strategies (choice of surgical
nd anesthetic technique, fluid management, intensified
ntraoperative and post-operative monitoring). However, it
as to be clearly pointed out that this NP-based approach is
peculative and, accordingly, needs to be rigorously evalu-
ted in well-designed prospective trials.
In conclusion, the study by Karthikeyan et al. (10) gives
mportant and clear evidence for a high prognostic potential
f NPs in patients scheduled for noncardiac surgery. How-
ver, studies to evaluate whether specific NP-based treat-
ent modifications will result in improved outcome of
urgical patients still need to be performed. Should future
tudies find outcome relevance of such a concept, NPs will
e indeed the magic bullet of pre-operative risk optimiza-
ion. So far, however, they are interesting and promising
ools for risk stratification that require further evaluation.
eprint requests and correspondence: Dr. Daniel Bolliger,
epartment of Anesthesia, University of Basel Hospital, CH-
031 Basel, Switzerland. E-mail: dabolliger@uhbs.ch.
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